Home › Funds › Checkpoint Capital L.P. › TRVI

Checkpoint Capital L.P. position in TRVI

TREVI THERAPEUTICS INC · Health Care

Checkpoint Capital L.P. reported holding 137,000 shares of TRVI (TREVI THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$2.0M, representing 0.44% of its reported portfolio and ranking #7 among its reported holdings. Checkpoint Capital L.P. has disclosed TRVI holdings in 8 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)137.00K sh
Reported value held$1.96M
Portfolio Weight0.44%
First reportedQ4 2023
Last changeAdd
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Checkpoint Capital L.P.'s TRVI position evolved

Checkpoint Capital L.P. first disclosed a stake in TRVI in Q4 2023 at 1,292,316 shares (US$1.7M). The position peaked in Q4 2024 at 1,084,135 shares, worth US$4.5M. Across 8 filings, Checkpoint Capital L.P. increased the stake 3 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 137,000 shares valued at US$2.0M — an increase of 62,000 shares quarter over quarter.. Notable position changes include a 61% trim in Q1 2024 (shares fell 14% over the following quarter), a 334% increase in Q4 2024 (shares rose 53% over the following quarter), a 83% increase in Q3 2026 (shares fell 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 1.29M $1.73M New
Q1 2024 506.08K $1.75M Reduce
Q2 2024 500.09K $1.49M Reduce
Q3 2024 250.00K $835.00K Reduce
Q4 2024 1.08M $4.47M Add
Q1 2026 50.00K $596.50K New
Q2 2026 75.00K $1.40M Add
Q3 2026 137.00K $1.96M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TRVI and 13F data

TRVI (TREVI THERAPEUTICS INC) is a Health Care company. 61 other funds we track also report a position in TRVI — the largest reported positions include NEA Management Company, LLC (US$246.6M), Frazier Life Sciences Management, L.P. (US$185.4M), Vivo Capital, LLC (US$60.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TRVI

All TRVI fund holders →

FAQ

How long has Checkpoint Capital L.P. held TRVI?

Checkpoint Capital L.P. has disclosed TRVI holdings in 8 of the last 12 reported quarters, going back to Q4 2023.

What is Checkpoint Capital L.P.'s current position in TRVI?

As of Q3 2026, Checkpoint Capital L.P. holds 137.00K shares of TRVI (TREVI THERAPEUTICS INC), valued at $1.96M, representing 0.44% of its reported portfolio and ranking #7.

Has Checkpoint Capital L.P. been buying or selling TRVI?

In the latest 13F filing (Q3 2026), Checkpoint Capital L.P. increased its position in TRVI. The position peaked in Q4 2024 at 1.08M shares.

Which other funds hold TRVI?

Other major institutional holders of TRVI include NEA Management Company, LLC, Frazier Life Sciences Management, L.P., Vivo Capital, LLC, among 61 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.